希玛医疗(03309.HK) 公布,向希华医药进行A系列投资,现金代价100万美元。完成后,预计集团将持有希华医药总股本约23%,后者是一间总部设于香港的临床阶段生物科技公司,拥有一系列口服抗癌项目。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.